Illumina, Inc. (NASDAQ:ILMN) Director Jay T. Flatley sold 20,000 shares of the stock in a transaction on Tuesday, August 15th. The shares were sold at an average price of $194.73, for a total value of $3,894,600.00. Following the completion of the transaction, the director now owns 539,176 shares in the company, valued at $104,993,742.48. The sale was disclosed in a document filed with the SEC, which is accessible through this hyperlink.

Shares of Illumina, Inc. (NASDAQ:ILMN) traded down 1.52% during mid-day trading on Thursday, reaching $191.20. The company had a trading volume of 659,906 shares. The firm has a market capitalization of $27.92 billion, a price-to-earnings ratio of 38.36 and a beta of 0.83. Illumina, Inc. has a one year low of $119.37 and a one year high of $199.95. The stock has a 50 day moving average of $181.07 and a 200-day moving average of $174.67.

Illumina (NASDAQ:ILMN) last issued its quarterly earnings results on Tuesday, August 1st. The life sciences company reported $0.82 EPS for the quarter, beating the Zacks’ consensus estimate of $0.68 by $0.14. The business had revenue of $662 million for the quarter, compared to analysts’ expectations of $642.38 million. Illumina had a net margin of 30.27% and a return on equity of 19.69%. The business’s quarterly revenue was up 10.3% compared to the same quarter last year. During the same quarter in the prior year, the firm posted $0.86 earnings per share. Equities analysts predict that Illumina, Inc. will post $3.65 EPS for the current year.

COPYRIGHT VIOLATION NOTICE: “Jay T. Flatley Sells 20,000 Shares of Illumina, Inc. (ILMN) Stock” was originally published by American Banking News and is the sole property of of American Banking News. If you are reading this news story on another publication, it was copied illegally and republished in violation of international trademark & copyright legislation. The legal version of this news story can be viewed at https://www.americanbankingnews.com/2017/08/17/jay-t-flatley-sells-20000-shares-of-illumina-inc-ilmn-stock.html.

ILMN has been the topic of a number of recent research reports. Deutsche Bank AG set a $175.00 price objective on Illumina and gave the company a “hold” rating in a research report on Friday, July 28th. Canaccord Genuity upgraded Illumina from a “hold” rating to a “buy” rating and increased their price objective for the company from $170.00 to $215.00 in a research report on Monday, August 7th. Vetr lowered Illumina from a “strong-buy” rating to a “buy” rating and set a $197.84 price objective on the stock. in a research report on Wednesday, June 21st. Morgan Stanley reiterated an “underweight” rating and issued a $122.00 price objective (up from $115.00) on shares of Illumina in a research report on Monday, July 10th. Finally, Barclays PLC reiterated a “hold” rating and issued a $150.00 price objective on shares of Illumina in a research report on Wednesday, July 19th. Three analysts have rated the stock with a sell rating, nine have assigned a hold rating and eleven have given a buy rating to the company’s stock. Illumina currently has a consensus rating of “Hold” and a consensus price target of $177.01.

A number of hedge funds have recently modified their holdings of ILMN. Jennison Associates LLC boosted its stake in shares of Illumina by 69.0% in the first quarter. Jennison Associates LLC now owns 5,254,274 shares of the life sciences company’s stock worth $896,589,000 after buying an additional 2,144,576 shares during the period. Winslow Capital Management LLC bought a new position in Illumina during the second quarter worth about $211,584,000. HPM Partners LLC boosted its position in Illumina by 29,103.8% in the second quarter. HPM Partners LLC now owns 751,999 shares of the life sciences company’s stock worth $107,724,000 after buying an additional 749,424 shares during the period. Fred Alger Management Inc. boosted its position in Illumina by 611.9% in the second quarter. Fred Alger Management Inc. now owns 637,597 shares of the life sciences company’s stock worth $110,636,000 after buying an additional 548,030 shares during the period. Finally, TIAA CREF Investment Management LLC boosted its position in Illumina by 55.6% in the second quarter. TIAA CREF Investment Management LLC now owns 1,475,669 shares of the life sciences company’s stock worth $256,058,000 after buying an additional 527,548 shares during the period. 93.91% of the stock is currently owned by institutional investors and hedge funds.

About Illumina

Illumina, Inc (Illumina) is a provider of sequencing- and array-based solutions for genetic analysis. The Company operates through two segments: Core Illumina and the consolidated variable interest entities (VIEs), which include the activities of GRAIL, Inc (GRAIL) and Helix Holdings I, LLC (Helix). Core Illumina consists of its core operations.

Insider Buying and Selling by Quarter for Illumina (NASDAQ:ILMN)

Receive News & Ratings for Illumina Inc. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Illumina Inc. and related companies with MarketBeat.com's FREE daily email newsletter.